Global respiratory system medicine sales in 2024 show Germany leading with $3.5 billion, followed by Spain at $1.76 billion. Significant growth rates over the last year include Austria (10.22%) and Australia (9.81%). Germany saw steady growth at 5.04%, while Japan experienced a decline of 4.14%. Switzerland and Belgium also showed consistent positive trends over recent years.
Among the smaller markets, Ireland, Finland, and Greece exhibited minimal fluctuations. Conversely, Hungary faced a noticeable decline at -5.8% in 2023. Looking ahead, Australia and Austria are expected to maintain robust growth, driven by new product launches and increasing healthcare investments.
Future trends to watch include the impact of emerging economies entering the market, advancements in technology driving new respiratory treatments, and global healthcare policy shifts. Monitoring these factors will be crucial for forecasting and adapting strategy in the respiratory system medicine market.
Top countries in Respiratory System Medicine Sales by Country
| # | 10 Countries | Million US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Germany | 3,500 | 2023 | +0.49% | +5.04% | View data |
| 2 | 2 Spain | 1,760 | 2023 | +0.98% | +2.15% | View data |
| 3 | 3 Japan | 892 | 2023 | -4.16% | -4.14% | View data |
| 4 | 4 Australia | 868.4 | 2023 | +3.04% | +9.81% | View data |
| 5 | 5 Belgium | 755.1 | 2023 | +0.12% | +4.22% | View data |
| 6 | 6 Switzerland | 606.4 | 2023 | -2.4% | +2.61% | View data |
| 7 | 7 Greece | 504.6 | 2023 | +1.55% | +0.38% | View data |
| 8 | 8 Austria | 358.7 | 2023 | +10.71% | +10.22% | View data |
| 9 | 9 Chile | 276.1 | 2023 | +1.62% | -3.13% | View data |
| 10 | 10 Ireland | 251.2 | 2023 | -0.12% | -1.15% | View data |
